These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 14602182)

  • 1. Influence of mechanical activation on the physical stability of salbutamol sulphate.
    Brodka-Pfeiffer K; Langguth P; Grass P; Häusler H
    Eur J Pharm Biopharm; 2003 Nov; 56(3):393-400. PubMed ID: 14602182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Following mechanical activation of salbutamol sulphate during ball-milling with isothermal calorimetry.
    Gaisford S; Dennison M; Tawfik M; Jones MD
    Int J Pharm; 2010 Jun; 393(1-2):74-8. PubMed ID: 20385222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Process-induced crystallinity changes in albuterol sulfate and its effect on powder physical stability.
    Ward GH; Schultz RK
    Pharm Res; 1995 May; 12(5):773-9. PubMed ID: 7479567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of small amorphous amounts in hydrophilic and hydrophobic APIs on storage stability of dry powder inhalation products.
    Müller T; Krehl R; Schiewe J; Weiler C; Steckel H
    Eur J Pharm Biopharm; 2015 May; 92():130-8. PubMed ID: 25769680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterisation of the influence of micronisation on the crystallinity and physical stability of revatropate hydrobromide.
    Ticehurst MD; Basford PA; Dallman CI; Lukas TM; Marshall PV; Nichols G; Smith D
    Int J Pharm; 2000 Jan; 193(2):247-59. PubMed ID: 10606789
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How does secondary processing affect the physicochemical properties of inhalable salbutamol sulphate particles? A temporal investigation.
    Pinto JT; Radivojev S; Zellnitz S; Roblegg E; Paudel A
    Int J Pharm; 2017 Aug; 528(1-2):416-428. PubMed ID: 28619456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of material attributes and process parameters on the micronisation of lactose monohydrate.
    Shariare MH; de Matas M; York P; Shao Q
    Int J Pharm; 2011 Apr; 408(1-2):58-66. PubMed ID: 21295125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of crystallisation conditions and feedstock morphology on the aerosolization performance of micronised salbutamol sulphate.
    Shariare MH; de Matas M; York P
    Int J Pharm; 2011 Aug; 415(1-2):62-72. PubMed ID: 21683128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Humidity-induced changes of the aerodynamic properties of dry powder aerosol formulations containing different carriers.
    Zeng XM; MacRitchie HB; Marriott C; Martin GP
    Int J Pharm; 2007 Mar; 333(1-2):45-55. PubMed ID: 17064863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigations on the humidity-induced transformations of salbutamol sulphate particles coated with L-leucine.
    Raula J; Thielmann F; Kansikas J; Hietala S; Annala M; Seppälä J; Lähde A; Kauppinen EI
    Pharm Res; 2008 Oct; 25(10):2250-61. PubMed ID: 18584311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A microcalorimetric investigation of the interaction of surfactants with crystalline and partially crystalline salbutamol sulphate in a model inhalation aerosol system.
    Blackett PM; Buckton G
    Pharm Res; 1995 Nov; 12(11):1689-93. PubMed ID: 8592671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Physicochemical and in vitro deposition properties of salbutamol sulphate/ipratropium bromide and salbutamol sulphate/excipient spray dried mixtures for use in dry powder inhalers.
    Corrigan DO; Corrigan OI; Healy AM
    Int J Pharm; 2006 Sep; 322(1-2):22-30. PubMed ID: 16815654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conditioning following powder micronization: influence on particle growth of salbutamol sulfate.
    Brodka-Pfeiffer K; Häusler H; Grass P; Langguth P
    Drug Dev Ind Pharm; 2003 Nov; 29(10):1077-84. PubMed ID: 14677768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Physico-chemical characterisation of surface modified particles for inhalation.
    Stank K; Steckel H
    Int J Pharm; 2013 May; 448(1):9-18. PubMed ID: 23518364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Measurement of low amounts of amorphous content in hydrophobic active pharmaceutical ingredients with dynamic organic vapor sorption.
    Müller T; Schiewe J; Smal R; Weiler C; Wolkenhauer M; Steckel H
    Eur J Pharm Biopharm; 2015 May; 92():102-11. PubMed ID: 25779351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel method for the production of crystalline micronised particles.
    Muhammad SA; Langrish T; Tang P; Adi H; Chan HK; Kazarian SG; Dehghani F
    Int J Pharm; 2010 Mar; 388(1-2):114-22. PubMed ID: 20043982
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dry powder inhalers: mechanistic evaluation of lactose formulations containing salbutamol sulphate.
    Kaialy W; Ticehurst M; Nokhodchi A
    Int J Pharm; 2012 Feb; 423(2):184-94. PubMed ID: 22197772
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reducing mechanical activation-induced amorphisation of salbutamol sulphate by co-processing with selected carboxylic acids.
    Curtin V; Amharar Y; Gallagher KH; Corcoran S; Tajber L; Corrigan OI; Healy AM
    Int J Pharm; 2013 Nov; 456(2):508-16. PubMed ID: 23994365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure and dissolution of L-leucine-coated salbutamol sulphate aerosol particles.
    Raula J; Seppälä J; Malm J; Karppinen M; Kauppinen EI
    AAPS PharmSciTech; 2012 Jun; 13(2):707-12. PubMed ID: 22562614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of drug particle shape on permeability and cellular uptake in the lung.
    Zellnitz S; Zellnitz L; Müller MT; Meindl C; Schröttner H; Fröhlich E
    Eur J Pharm Sci; 2019 Nov; 139():105065. PubMed ID: 31493448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.